OncoMatch/Clinical Trials/NCT05952024
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Is NCT05952024 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Rituximab and Acalabrutinib for diffuse large b-cell lymphoma.
Treatment: Acalabrutinib · Rituximab — The study will measure the safety, tolerability, and efficacy with acalabrutinib in combination with rituximab in treatment-naïve elderly and/or frail patients with diffuse large B-cell lymphoma (DLBCL), who are otherwise unsuitable for standard front line chemoimmunotherapy treatments.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Disease stage
Required: Stage II, III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Lab requirements
Blood counts
Adequate organ and marrow function independent of growth factor or transfusion support within 1 week of Screening.
Kidney function
Adequate organ and marrow function independent of growth factor or transfusion support within 1 week of Screening.
Liver function
Adequate organ and marrow function independent of growth factor or transfusion support within 1 week of Screening.
Adequate organ and marrow function independent of growth factor or transfusion support within 1 week of Screening.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · La Jolla, California
- Research Site · Orange, California
- Research Site · Jacksonville, Florida
- Research Site · Waukee, Iowa
- Research Site · Baltimore, Maryland
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05952024 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage II or III or IV is required.
Is there an age limit?
Yes. Patients must be 99 years or younger and at least 65 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify